Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : to seek US approval of COVID vaccine in 2nd half

07/29/2021 | 11:01am EDT

LONDON (AP) — AstraZeneca said Thursday that it intends to seek U.S. approval for its COVID-19 vaccine later this year, further delaying the application even as the company announced it had already delivered more than 1 billion doses to other countries.

The Anglo-Swedish drugmaker said the application has been delayed because it has decided to ask the U.S. Food and Drug Administration for full regulatory approval, rather than the fast-track emergency use authorization originally anticipated. As part of this “biologics license application,” the FDA has requested extensive data from clinical trials around the world, as well as data on real world use of the vaccine.

“We have an enormous amount of data, clinical data and all of the data coming from the work we’ve done around the world,″ AstraZeneca CEO Pascal Soriot said on a conference call with reporters. “A BLA is a much bigger submission than the emergency use approval.”

AstraZeneca has promoted its relatively cheap, easy-to-handle shot as a “vaccine for the world” and has already received authorization from more than 170 countries. The company, which has promised to deliver the vaccine on a non-profit basis throughout the pandemic, says it provided about 90% of the doses distributed by the COVAX facility for low- and middle-income countries in the first half of the year.

AstraZeneca is the second drugmaker to say it has delivered more than 1 billion doses of COVID-19 vaccine, following U.S.-based Pfizer’s announcement on Wednesday.

Oxford University scientists who developed the AstraZeneca vaccine applauded the company and its partners for reaching the landmark but noted that most people around the world haven’t been inoculated against a disease that has already killed more than 4.1 million people worldwide.

“There is still so much to do, and all in the supply chain are pushing on knowing the next billion people are still waiting for their doses,” said Andrew Pollard, director of the Oxford Vaccine Group.

Plans for AstraZeneca’s U.S. application are being closely watched because the timetable has slipped in recent months. When AstraZeneca released data from its U.S. vaccine trial on March 22, company officials said they expected to seek FDA authorization in April.

Among the concerns AstraZeneca will have to address are reports that the vaccine may be linked to rare blood clots, which have caused some countries to limit its use in younger people.

While the U.S. is currently “well supplied” with vaccines, AstraZeneca believes its shot could “play a role in the future,” Soriot said.

“It’s a good vaccine, and we just want to make sure it’s ready to be used if needed,” he said.

AstraZeneca said Thursday that sales of its COVID-19 vaccine generated $1.17 billion in revenue during the first six months of the year. By contrast, Pfizer reported $11.3 billion of revenue from its vaccine during the same period.

When asked about Pfizer’s results, Soriot said he had no regrets about AstraZeneca’s strategy.

“We don’t envy anybody,” he said.

The vaccine was developed by Oxford University researchers, who licensed the technology to AstraZeneca to tap into the company’s global manufacturing and distribution capacity. AstraZeneca, in turn, authorizes other companies to produce the shots around the world.

During the first half of the year, AstraZeneca and its partners delivered more than 700 million doses of the vaccine, data ending June 30 showed. That included about 319 million doses produced by AstraZeneca and 381 million doses produced by the Serum Institute of India and other sub-licensees.

Despite complaints from the EU about its vaccine supply, the 27-nation bloc received more doses directly from AstraZeneca than any other single entity in the six months through June.

The company shipped 97 million doses to the EU, while Brazil got 65 million doses and the U.K. 52 million, AstraZeneca said. Gavi, an alliance that secures vaccines for low-income countries, received 49 million doses, and another 57 million doses went to other countries.

Ruud Dobber, president of AstraZeneca's BioPharmaceuticals business unit, said the company is working with the EU to resolve the bloc’s concerns and avoid a protracted legal dispute.

“We don’t think it’s useful for both parties to continue this,” he said. “And I’m very hopeful that in the next few weeks we will come to an agreement.”


Follow more of AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic and https://apnews.com/hub/coronavirus-vaccine.

Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News

All news about ASTRAZENECA PLC
10:06aShangula Rages Against West's Vaccine Nationalism
08:35aASTRAZENECA : India calls new UK COVID-19 vaccine rules 'discriminatory'
07:02aASTRAZENECA : Investment will transform development and commercialisation of new medicines..
06:23aEUROPEAN MIDDAY BRIEFING : Stocks Rebound But -2-
05:42aASTRAZENECA : to Invest $360 Million in New Irish Manufacturing Facility
02:51aCapital.com Announces Top Hire to Drive Growth in Asia
02:45aAstraZeneca to invest $360 million in Irish drug manufacturing site
02:25aASTRAZENECA : Plans New $360 Million Irish Manufacturing Site
02:12aASTRAZENECA : to invest $360m in advanced manufacturing facility in Ireland
12:23aAstraZeneca to Build $360 Million Manufacturing Plant in Dublin
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 401 M - -
Net income 2021 5 006 M - -
Net Debt 2021 24 250 M - -
P/E ratio 2021 32,7x
Yield 2021 2,41%
Capitalization 181 B 181 B -
EV / Sales 2021 5,80x
EV / Sales 2022 4,70x
Nbr of Employees 76 100
Free-Float 96,3%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 27
Last Close Price 116,93 $
Average target price 135,96 $
Spread / Average Target 16,3%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC16.86%181 312
JOHNSON & JOHNSON4.09%431 227
ROCHE HOLDING AG10.52%321 941
PFIZER, INC.19.23%247 816
NOVO NORDISK A/S48.69%229 255